ProFound Therapeutics key facts
as of Oct 2026- Developer of a novel therapeutic target discovery platform designed to make a profound impact on human health.
- ProFound Therapeutics is valued at approximately $310.0M as of Oct 2026 (last reported valuation).
- It has raised $162.7M; the latest was Later Stage VC ($50.0M) in Feb 2025.
- Notable investors include Samsung Venture Investment, Modi Ventures, Flagship Pioneering, Notley Ventures.
- Status: Privately Held (backing).
ProFound Therapeutics's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·Watch ProFound Therapeutics: the Monday email on marks, rounds and moves
ProFound Therapeutics funding rounds
No funding rounds for ProFound Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ProFound Therapeutics
4ProFound Therapeutics valuation
ProFound Therapeutics's last reported valuation was $310 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
ProFound Therapeutics investors
4 investors are on record for ProFound Therapeutics, including Samsung Venture Investment, Modi Ventures, Flagship Pioneering and Notley Ventures.
About ProFound Therapeutics
Developer of a novel therapeutic target discovery platform designed to make a profound impact on human health. The company's platform uses protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential, enabling biotech researchers to get a database of novel proteins, including their connectivity, functionality, and roles in health and disease.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 46
- Website
- profoundtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.